Akèy › Timè neuroendokrin gastro-enteropancreatik
Etid klinik pou Timè neuroendokrin gastro-enteropancreatik ap rekrite nan Etazini
7 etid pou Timè neuroendokrin gastro-enteropancreatik ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
Pa eta
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
Ap rekriteFaz 1
24 Months – 18 Years · Tout sèks · Mizajou Sep 25, 2026 · NCT06441331Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT07165132Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Ap rekriteFaz 3
Laj 12 a 100 · Tout sèks · Mizajou Sep 11, 2026 · NCT06784752A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
Ap rekriteEtid obsèvasyon
Laj 18 a 110 · Tout sèks · Mizajou Jul 6, 2026 · NCT07635316Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Ap rekriteFaz 1/2
Laj 18 a 90 · Tout sèks · Mizajou May 14, 2026 · NCT05636618Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Mar 20, 2026 · NCT04090034Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Mar 2, 2026 · NCT07150546Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.